Dexmedetomidine directly binds to and inhibits Toll-like receptor 4
International Immunopharmacology · 2024-11 · 141 · 112975
DOI: 10.1016/j.intimp.2024.112975 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Sophia Koutsogiannaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, USA; Department of Anaesthesia, Harvard Medical Sc…. Hauptthemen laut MEDLINE: Dexmedetomidine, Toll-Like Receptor 4, Microglia, Rats, Sprague-Dawley. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIGMS.
Abstract (Originalsprache)
BACKGROUND: While a number of anesthetics has been shown potentially associated with neurotoxicity in the developing brain, dexmedetomidine, a drug that was rather recently introduced into the perioperative setting, is considered beneficial from neurological wellbeing. However, the underlying mechanism of how dexmedetomidine affects brain health remains to be determined. Based on our recent study, we hypothesized that dexmedetomidine would directly bind to and inhibit Toll-like receptor 4 (TLR4), a critical receptor largely expressed in microglia and responsible for neurological insult. METHODS: We used TLR4 reporter assays to test if dexmedetomidine attenuates TLR4 activation. Furthermore, a direct binding of dexmedetomidine on TLR4 was tested using photoactivatable medetomidine. Lastly, the effect of dexmedetomidine on ketamine (anesthetic)-induced neurotoxicity was tested in rat pups (P7). RESULTS: We showed that dexmedetomidine attenuated TLR4 activation using reporter assay (IC50 = 5.8 µg/mL). Photoactivatable dexmedetomidine delineated its direct binding sites on TLR4. We also showed that dexmedetomidine attenuated microglia activation both in vitro and in vivo. DISCUSSION: We proposed a novel mechanism of dexmedetomidine-mediated neuroprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, USA; Department of Anaesthesia, Harvard Medical School, Boston, USA; Department of Immunology, Harvard Medical School, B…
- Department of Anesthesia and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, USA.
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Japan.
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, USA; Department of Anaesthesia, Harvard Medical School, Boston, USA.
Förderung
- NIGMS NIH HHS
- NIGMS
Zitieren
APA
Koutsogiannaki, S., Limratana, P., Bu, W., Maisat, W., McKinstry-Wu, A., Han, X., Ohto, U., Eckenhoff, R. G., Soriano, S. G., & Yuki, K. (2024). Dexmedetomidine directly binds to and inhibits Toll-like receptor 4. International Immunopharmacology, 141, 112975. https://doi.org/10.1016/j.intimp.2024.112975
Vancouver
Koutsogiannaki S, Limratana P, Bu W, Maisat W, McKinstry-Wu A, Han X, et al. Dexmedetomidine directly binds to and inhibits Toll-like receptor 4. International Immunopharmacology. 2024;141:112975. doi:10.1016/j.intimp.2024.112975
BibTeX
@article{Koutsogiannaki2024,
author = {Koutsogiannaki, Sophia and Limratana, Panop and Bu, Weiming and Maisat, Wiriya and McKinstry-Wu, Andrew and Han, Xiaohui and Ohto, Umeharu and Eckenhoff, Roderic G and Soriano, Sulpicio G and Yuki, Koichi},
title = {Dexmedetomidine directly binds to and inhibits Toll-like receptor 4},
journal = {International Immunopharmacology},
year = {2024},
volume = {141},
pages = {112975},
doi = {10.1016/j.intimp.2024.112975}
}
EUVIMED